Trial Profile
A Phase II, Open-Label Study of Bortezomib (Velcade), Cladribine and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cladribine (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 15 Feb 2019 Status changed from active, no longer recruiting to completed.
- 24 Apr 2018 Planned primary completion date changed from 1 Dec 2015 to 31 Dec 2020.
- 06 Dec 2016 Results (n=24) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology